Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
24.55
-2.49 (-9.21%)
Nov 22, 2024, 4:00 PM EST - Market closed
Q32 Bio Revenue
Q32 Bio had revenue of $-14.66M in the twelve months ending September 30, 2024, down -224.35% year-over-year. In the year 2023, Q32 Bio had annual revenue of $-6.65M, down -200.00%.
Revenue (ttm)
$-14.66M
Revenue Growth
-224.35%
P/S Ratio
n/a
Revenue / Employee
$-396,270
Employees
37
Market Cap
299.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | -6.65M | -13.30M | -200.00% |
Dec 31, 2022 | 6.65M | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionQTTB News
- 16 days ago - Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 18 days ago - Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - PRNewsWire
- 5 weeks ago - Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 - PRNewsWire
- 3 months ago - Q32 Bio to Participate in Upcoming September Investor Conferences - PRNewsWire
- 3 months ago - Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097 - Seeking Alpha
- 4 months ago - 8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803% - Benzinga
- 4 months ago - Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis - PRNewsWire
- 5 months ago - Q32 Bio Joins Russell 3000® Index - PRNewsWire